Travere Therapeutics (TVTX) Stock Price, News & Analysis

-0.63 (-9.42%)
(As of 05/17/2024 ET)
Today's Range
50-Day Range
52-Week Range
1.32 million shs
Average Volume
1.34 million shs
Market Capitalization
$461.35 million
P/E Ratio
Dividend Yield
Price Target

Travere Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.64 Rating Score
175.5% Upside
$16.69 Price Target
Short Interest
16.83% of Shares Sold Short
Dividend Strength
News Sentiment
0.11mentions of Travere Therapeutics in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$364 Sold Last Quarter
Proj. Earnings Growth
From ($3.66) to ($1.72) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.93 out of 5 stars

Medical Sector

783rd out of 921 stocks

Pharmaceutical Preparations Industry

360th out of 418 stocks

TVTX stock logo

About Travere Therapeutics Stock (NASDAQ:TVTX)

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

TVTX Stock Price History

TVTX Stock News Headlines

Gossamer Bio: Q1 Earnings Snapshot
See More Headlines
Receive TVTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Travere Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
14 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$145.24 million
Book Value
$0.97 per share


Free Float
Market Cap
$461.35 million
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

TVTX Stock Analysis - Frequently Asked Questions

Should I buy or sell Travere Therapeutics stock right now?

14 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Travere Therapeutics in the last twelve months. There are currently 5 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" TVTX shares.
View TVTX analyst ratings
or view top-rated stocks.

What is Travere Therapeutics' stock price target for 2024?

14 analysts have issued 1-year price objectives for Travere Therapeutics' shares. Their TVTX share price targets range from $9.00 to $30.00. On average, they expect the company's share price to reach $16.69 in the next twelve months. This suggests a possible upside of 175.5% from the stock's current price.
View analysts price targets for TVTX
or view top-rated stocks among Wall Street analysts.

How have TVTX shares performed in 2024?

Travere Therapeutics' stock was trading at $8.99 at the beginning of the year. Since then, TVTX shares have decreased by 32.6% and is now trading at $6.06.
View the best growth stocks for 2024 here

When is Travere Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024.
View our TVTX earnings forecast

How were Travere Therapeutics' earnings last quarter?

Travere Therapeutics, Inc. (NASDAQ:TVTX) issued its earnings results on Monday, May, 6th. The company reported ($1.76) EPS for the quarter, missing analysts' consensus estimates of ($0.98) by $0.78. The firm had revenue of $41.40 million for the quarter, compared to the consensus estimate of $43.46 million. Travere Therapeutics had a negative net margin of 87.94% and a negative trailing twelve-month return on equity of 238.06%. The company's quarterly revenue was up 34.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($1.27) EPS.

What ETF holds Travere Therapeutics' stock?

Virtus LifeSci Biotech Products ETF holds 44,150 shares of TVTX stock, representing 1.39% of its portfolio.

Who are Travere Therapeutics' major shareholders?

Travere Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (8.23%), Jacobs Levy Equity Management Inc. (1.48%), Assenagon Asset Management S.A. (0.29%), Healthcare of Ontario Pension Plan Trust Fund (0.27%), Russell Investments Group Ltd. (0.24%) and Affinity Asset Advisors LLC (0.16%). Insiders that own company stock include Christopher R Cline, Elizabeth E Reed, Eric M Dube, Jula Inrig, Laura Clague, Noah L Rosenberg, Peter Heerma, Sandra Calvin, Steve Aselage and William E Rote.
View institutional ownership trends

How do I buy shares of Travere Therapeutics?

Shares of TVTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:TVTX) was last updated on 5/19/2024 by Staff

From Our Partners